LIXT
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Next earnings Aug 5, 2026
$7.19
▲ +8.12%$7.19▲ +810.13%
over 1Y
L $0.71EODHDH $7.61
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+8.1%
1W-3.9%
1M+12.0%
3M+132.7%
YTD+87.2%
1Y+810.1%
Sell
Conviction
Horizon
Medium (3–12mo)
Conservative balance sheet (liabilities/equity 0.18x); but unprofitable (net margin -3039.3%).
Revenue (FY2015) $200K · FY2015
LIXTE BIOTECHNOLOGY HOLDINGS, INC. shows $200K in FY2015 revenue, a -3039.3% net margin, and -62.9% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$6.72M | -$6.31M | -$5.09M | -$3.57M | -$5.11M |
| Net income | -$6.73M | -$6.31M | -$5.09M | -$3.59M | -$6.08M |
| Diluted EPS | — | -$3.99 | -$2.66 | -$1.59 | -$1.26 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$79.3M
EV / EBITDA—
EV / Sales396.6
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-7.3%
FCF yield—
Quality & risk
ROIC (est.)-41.8%
Free cash flow—
Total debt—
Net cash$4.20M
Altman Z-Score20.95 safe
Piotroski F-Score4/7
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+332.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Material agreement2026-06-18
- 8-K Material agreement2026-06-16
- 8-K Material agreement2026-06-04
- 8-K Officer / director change2026-06-01
- 10-Q Quarterly report2026-05-14
- 8-K Officer / director change2026-04-17
- 10-K Annual report2026-03-31
- 8-K Officer / director change2026-03-20
- 10-Q Quarterly report2025-11-12
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-172026-06-18open ↗8-KPeriod ending 2026-06-112026-06-16open ↗SCHEDULE 13GFiling2026-06-09open ↗8-KPeriod ending 2026-06-022026-06-04open ↗424B5Filing2026-06-04open ↗4Period ending 2026-05-292026-06-01open ↗3Period ending 2026-05-292026-06-01open ↗8-KPeriod ending 2026-05-292026-06-01open ↗10-QPeriod ending 2026-03-312026-05-14open ↗4Period ending 2026-04-152026-04-17open ↗4Period ending 2026-04-152026-04-17open ↗4Period ending 2026-04-152026-04-17open ↗
Frequently asked
- Is LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) a buy?
- LIXT currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.18x); but unprofitable (net margin -3039.3%).
- What is LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s quality score?
- LIXT scores 31/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001335105, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 2:04:34 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.